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Abstract
Background: To analyse whether the availability of written standards for management of mechanically ventilated
patients and/or the existence of a surveillance system for cases of ventilation-associated pneumonia (VAP) are
positively associated with compliance with 6 well-established VAP prevention measures.
Methods: Ecological study based on responses to an online-questionnaire completed by 1730 critical care physicians.
Replies were received from 77 different countries, of which the majority, i.e. 1351, came from 36 European countries.
Results: On a cross-country level, compliance with VAP prevention measures is higher in countries with a large number
of prevention standards and/or VAP surveillance systems in place at ICU level., Likewise, implementation of standards
and VAP surveillance systems has a significant impact on self-reported total compliance with VAP prevention measures
(both p < 0.001). Moreover, predictions of overall prevention measure compliance show the effect size of the availability
of written standards and existence of surveillance system. For instance, a female physician with 10 years of experience
in critical care working in a 15-bed ICU in France has a predicted baseline level of VAP prevention measure compliance
of 63 per cent. This baseline level increases by 9.5 percentage points (p < 0.001) if a written clinical VAP prevention
standard is available in the ICU, and by another 4 percentage points (p < 0.001) if complemented by a VAP surveillance
system.
Conclusions: The existence of written standards for management of mechanically ventilated patients in an ICU and
the availability of VAP surveillance systems have shown to be positively associated with compliance with VAP
prevention measures and should be fostered on a policy level.
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Introduction
Healthcare-associated infections (HAIs) are considered
to be a major risk for hospitalised patients and the cause
of substantial increases in morbidity, mortality and costs
in European Union (EU) member states. Approximately
7 percent of hospitalized patients acquire an HAI while
receiving treatment for medical or surgical conditions
[1], and it is estimated that each year approximately
37,000 lives are lost to HAI in the EU alone. Healthcare-
associated infections incur an estimated Euro 7 billion in
excess healthcare costs per annum in the EU, caused
mainly by increased length of hospital stay [2]. HAIs are
associated with a variety of causes, including but not
limited to use of medical devices such as catheters and
ventilators, complications following surgical procedures,
transmission of pathogens or antibiotic overuse [3,4]. HAIs
are often difficult to treat due to antimicrobial resistance
(AMR) of the microorganisms causing them [5]. There is a
public health interest in preventing HAIs, as laid out in the
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European Council recommendation of 9th June 2009
in which HAI prevention measures were adopted as
part of patient safety programs and quality improve-
ment initiatives [6,7]. National HAI-prevention programs
include establishment of surveillance systems, publication
of guidelines and measuring structure and process indica-
tors. Furthermore, some European countries have estab-
lished public reporting of data on HAI from individual
hospitals [8,9].
Pneumonia was the HAI most frequently reported in
the ECDC pilot point prevalence survey [1], and is most
common in the intensive care unit (ICU) [10,11], where a
relevant proportion of patients receive mechanical ventila-
tion. Many studies provide evidence for the preventive
effectiveness of single interventions, leaving the decision-
maker with the complex task of selecting the best one
[12-16]. Recently, there has been dramatic success in im-
proving the quality of patient care by focusing on the imple-
mentation of an entire group or “bundle” of evidence-based
preventive practices [17-19]. These bundle approaches
achieve better outcomes than individual implementation
of single procedures [20-24], and, from the hospital per-
spective, have shown to be cost-effective [25,26].
The infection prevention and control measures that have
been applied in hospitals to reduce ventilator-associated
pneumonia (VAP) vary widely, both within and between
different countries [27]. A harmonized approach, based on
the application of core strategies developed through an
evidence-based approach and comprising specific strat-
egies which relate to local characteristics and context
e.g., the affected patient case-mix, should result in a more
comparable situation. However, consensus is missing on
the most effective infection control interventions or the
best combination of interventions to reduce VAP in hospi-
talized patients. Therefore, we performed a survey to define
the level of heterogeneity and analyse related outcomes.
In detail, we used the information collected in a question-
naire completed by 1730 ICU physicians across Europe
and around the world to analyze whether the availability
of written standards for the management of mechan-
ically ventilated patients and/or the existence of a VAP
surveillance system on ICU-level are positively associated
with compliance with a number of well-established VAP
prevention measures.
Methods
The dataset
The present work is based on a comprehensive internet-
based survey of 1730 ICU physicians. The questionnaire
was available online from April 1 to September 1, 2012
and was distributed through various channels by the
European Society of Intensive Care Medicine, by national
ICU societies in Austria, France, Belgium, the Netherlands,
Italy, and Greece as well as through the Revista Electronica
de Medicina Intensiva, an electronic newsletter on in-
tensive care medicine in Spanish distributed in Spain,
Portugal, and Latin America [28]. Accordingly, the under-
lying response rate of the survey was unknown. Overall,
we received replies from 77 different countries world-
wide, of which the majority i.e. 1351 replies came from 36
European countries (including Cyprus, Georgia, Turkey
and the Russian Federation). Participation in the survey
was anonymous and, as no patient-related information
but only process indicators were asked, ethical approval
was not necessary [29,30]. See Table 1 for details of the
countries with most responses (n > 20). The exact details
of the overall survey are already described elsewhere
[28,31,32]. The present work applies a cross-country com-
parison of selected survey results in order to analyse
factors influencing compliance with a number of well-
established VAP prevention measures. Essentially, the
survey generated information about (1) country of abode,
(2) some aspects about the hospital in which the physician
works, (3) a large number of parameters relating to the
ICU in which the physician works and (4) a number of
person-specific parameters. With respect to the ICU level,
two aspects of the survey are of particular interest for this
analysis: Firstly, the physicians were asked to answer the
following question (yes/no): “In my ICU, we have writ-
ten clinical guidelines for the prevention of ventilator-
associated pneumonia” (in the following referred to as
existence of VAP-standard). Secondly, the physicians an-
swered the question (yes/no) “In my ICU, we count and
record VAP on a routine basis” (in the following referred
to as existence of VAP surveillance system). Thirdly, the
physicians were asked whether, care for intubated patients
in their ICU included the following measures: (1) Head of
bed elevation; (2) Daily sedation and weaning protocol;
(3) Oral care with chlorhexidine; (4) No ventilator circuit
change unless indicated; (5) Cuff pressure control at least
every 24 hrs; (6) Strict hand hygiene using alcohol, espe-
cially before managing the airways (in the following
referred to as compliance with prevention measure
(1) – (6)). In addition to these 6 specific VAP prevention
measures, we determined a variable of overall compliance
(compliance-score) by simply adding up self-reported
compliance with the 6 specific measures. If for instance all
6 measures are applied in the particular ICU, this variable
is equal to 6; if however only two measures are applied
the variable is equal to 2.
Although there is no universally accepted gold stand-
ard for prevention of VAP, a recent study defined a
European care bundle for prevention of VAP and ranked
VAP prevention measures by combining criteria such as
the strength of the supporting evidence, ease of implemen-
tation and expected impact on VAP incidence [33]. The
top five clinical interventions of this ranking were included
in our questionnaire (VAP prevention measure 2–6). As a
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Table 1 Non-representative country averages for countries with >20 responses
Country Number of
responses
Number of
pseudo-ICUs
Mean years
of experience
in critical care
Proportion
female sex
Number
of beds
in ICU
Availability of
VAP prevention
standards
Existence of VAP
surveillance
system
VAP
measure 1
VAP
measure 2
VAP
measure 3
VAP
measure 4
VAP
measure 5
VAP
measure 6
Sum of VAP
measures 1-6
AR 40 24 15.00 25% 13.20 65% 68% 100% 63% 73% 98% 78% 78% 4.88
AT 130 58 12.75 35% 8.97 40% 45% 96% 44% 47% 93% 98% 82% 4.59
AU 23 17 14.17 9% 19.43 30% 30% 100% 48% 39% 70% 100% 91% 4.48
BE 33 25 17.21 24% 21.15 73% 48% 100% 52% 91% 55% 97% 94% 4.88
BR 21 18 13.86 10% 20.71 81% 76% 100% 71% 86% 95% 62% 67% 4.81
CH 29 16 9.90 24% 12.93 69% 38% 97% 69% 72% 86% 86% 93% 5.03
CO 31 19 9.45 29% 14.84 68% 74% 97% 55% 84% 87% 77% 97% 4.97
DE 67 49 11.81 15% 22.93 67% 52% 97% 54% 60% 93% 99% 84% 4.85
ES 293 107 16.10 38% 15.80 81% 74% 98% 43% 94% 93% 93% 87% 5.09
FR 251 113 11.50 24% 14.88 47% 61% 96% 19% 55% 69% 90% 94% 4.24
GB 115 57 10.74 22% 17.16 79% 50% 98% 81% 90% 50% 87% 87% 4.92
GR 23 15 11.35 61% 11.00 30% 39% 96% 30% 83% 61% 52% 74% 3.96
IN 63 44 9.25 6% 23.94 81% 79% 100% 95% 90% 84% 81% 97% 5.48
IT 187 56 15.47 34% 8.34 60% 48% 91% 35% 76% 50% 70% 70% 3.93
MX 31 19 10.97 10% 10.16 52% 68% 97% 42% 39% 87% 90% 81% 4.35
NL 31 22 9.06 16% 20.87 81% 39% 81% 61% 35% 68% 84% 87% 4.16
PE 23 15 14.52 9% 12.96 43% 57% 96% 48% 4% 91% 78% 48% 3.65
PT 50 27 12.46 42% 12.18 58% 68% 100% 38% 80% 68% 78% 84% 4.48
Availability of VAP prevention standards: country averages of positive responses to the question (yes/no): “In my ICU, we have written clinical guidelines for the prevention of ventilator-associated pneumonia”.
Existence of VAP surveillance system: country averages of positive responses to the question (yes/no): “in my ICU, we count and record VAP on a routine basis”.
VAP prevention measure 1: Head of bed elevation; VAP prevention measure 2: daily sedation and weaning protocol; VAP prevention measure 3: Oral care with chlorhexidine; VAP prevention measure 4: No ventilator
circuit change unless indicated; VAP prevention measure 5: Cuff pressure control at lease every 24 hrs; VAP prevention measure 6: Strict hand hygiene using alcohol.
Only countries with >20 responses are included in Table 1.
Country appreviations: ES = SPAIN; FR = FRANCE; IT = ITALY; AT = AUSTRIA; GB = UNITED KINGDOM; DE = GERMANY; IN = INDIA; PT = PORTUGAL; AR = ARGENTINA; BE = BELGIUM; CO = COLOMBIA; MX =MEXICO;
NL = NETHERLANDS; CH = SWITZERLAND; AU = AUSTRALIA; GR = GREECE; PE = PERU; BR = BRAZIL.
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control, the most commonly recommended clinical prac-
tice of head of bed elevation was included in the survey
and analyzed as VAP prevention measure 1. Accordingly,
self-reported compliance with the target VAP prevention
measures were interpreted as compliance with bundle-like
VAP prevention measures under routine conditions.
Statistical analysis
The statistical analysis consisted of three steps. In a first
step, country-specific averages of stated compliance with
specific VAP prevention measures univariately regressed
against the country-average responses to the questions
on whether there were written clinical guidelines in place
on ICU level for prevention of VAP (and whether there
were VAP surveillance systems in place). The results pro-
vide a first insight into the relationship between described
variables on a cross-country level. Next, within-country
averages of stated compliance with the VAP prevention
measures were calculated separately for physicians stating
whether their ICU had written VAP-standards or not (and
whether they had VAP surveillance systems in place or
not). Thus, the evidence from these within-country differ-
ences in average compliance with the VAP prevention
measures was summarized by a p-value from a paired
Student’s t-test. In a further step, we endeavoured to
utilize the information on inter-ICU differences, i.e. on
whether associations exist at ICU-level within each coun-
try. Unfortunately, the ICU of each participant is not
known. Because our main outcome was defined at ICU
level – i.e. compliance with 6 specific measures, we were
forced to define pseudo-ICUs by analysing patterns in the
ICU characteristics reported by the participants (country
of abode, ICU type, number of beds in ICU and number
of beds in hospital) and then grouping participants with
similar patterns into pseudo-ICUs. This was done in a ra-
ther liberal manner to ensure that each existing ICU was
covered by a pseudo-ICU, at the same time allowing for
pseudo-ICUs to cover several responses. For ICU type and
number of beds in hospital only three answers were pos-
sible (ICU type: medical, surgical, mixed; number of beds
in hospital: < 300, 300–1000, > 1000) while number of
beds in an ICU was a continuous variable. The number of
ICUs we were able to define this way in the different
countries is shown in Table 1. Within each pseudo-ICU
we have some variation in the individual responses, which
both reflects the flaws in the pseudo-ICUs and the differ-
ences in the individual responses within an ICU. We
therefore decided to perform an analysis at the individual
level, taking however both country and pseudo-ICU levels
into account to avoid an overoptimistic assessment of the
statistical significance since we had ignored the high cor-
relations between the outcomes within each ICU. More-
over, using pseudo ICUs instead of the true ICUs results
in more valid p-values here because possible and to some
extent unknown clustering is taken into account. We used
linear regression/logistic regression models with the co-
variates of interest, adjusting for country (as a categorical
covariate) as well as number of beds, gender and experi-
ence as individual measurements, and took the clustering
within pseudo ICUs into account by using robust standard
errors (application of the cluster option in Stata 12). Using
pseudo ICUs instead of ICUs is a valid approach here be-
cause the central assumption of independence of the out-
comes between clusters is still valid, even if the clusters
are bigger than necessary. As covariates of interest we in-
cluded presence of written clinical standards on ICU level
and presence of VAP surveillance systems.
Results
Standard existence and compliance with VAP prevention
measures
As shown in Figure 1, country averages for countries where
there were more than 20 responses of self-reported compli-
ance with the different VAP prevention measures are posi-
tively associated with the country-averages of self-reported
presence of written clinical standards for prevention of
VAP on the ICU level (p < 0.01).
Furthermore, Figure 2 shows that in most countries
where there were more than 20 responses, average self-
reported compliance with the different VAP prevention
measures is higher when the respondents also confirmed
presence of written VAP prevention standards on ICU level
(p < 0.01). Correspondingly, we can postulate a connection
between compliance with VAP prevention measures and
the presence of VAP prevention standards on the between-
country (Figure 1) and within-country (Figure 2) level.
As shown in Additional file 1: Figure S1 (available as sup-
plemental material), the results displayed by individual pre-
vention measures provide mixed results. VAP prevention
measure 1 - head of bed elevation - is commonly recom-
mended clinical practice with high rates of compliance;
however, when looking at the between-country or within-
country averages there does not seem to be an obvious con-
nection with the presence of VAP prevention standards.
Regarding VAP prevention measure 2 and 3, which refer to
daily sedation vacation and weaning protocol and oral care
with chlorhexidine, there seems to be a connection between
the respective prevention measure and the existence of
VAP prevention standards when regarding the between-
country and within- country averages. Regarding VAP pre-
vention measure 4 and 5, which refer to no ventilator
circuit change unless indicated and cuff pressure control at
least every 24 hrs, the country-averages show no clear con-
nection. VAP prevention measure 6, which represents strict
hand hygiene using alcohol, especially before managing the
airways, shows quite a strong association when looking at
the within-country averages, but absolutely no association
when looking at the between-country averages.
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Existence of VAP surveillance system and compliance
with VAP prevention measures
As shown in Figure 3, country averages of self-reported
compliance with the different VAP prevention measures
are positively associated with the country averages of
self-reported existence of a VAP surveillance system at
the 10 percent level only (p = 0.08).
On the other hand, the connection between prevention
measure compliance and existence of a surveillance sys-
tem appears to be more obvious on the within-country
level (See Figure 4).
Results of statistical analysis at the individual level
The regression analyses applied take both the interrelation
within and between countries into account and show a
significant independent association between most of the
VAP prevention measures and the existence of written
VAP prevention standards on ICU level (see regression
(1) to (6) in Table 2). Please note that the non-significance
with respect to VAP prevention measure 1 may be a result
of the ceiling effect since compliance with the commonly
recommended clinical practice of head of bed elevation is
very high (see Table 1). The existence of a VAP surveillance
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Figure 2 Mean VAP Guideline existence and self-reported compliance with VAP prevention measures within countries.
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system, however, has a slightly smaller impact on compli-
ance with the specific measures. Column (7) in Table 2
shows the results of the analysis in which the variable of
total compliance (compliance-score) is placed on the left-
hand side of the regression analysis. In detail, the analyses
show that existence of standard and VAP surveillance sys-
tems impact substantially on total compliance with the
VAP prevention measures (both p < 0.001). The country-
specific implications of regression (7) may be interpreted
as follows: According to our model, a female physician
with 10 years of experience in critical care working in a 15-
bed ICU in France for instance has a predicted baseline
level of VAP prevention measure compliance (compliance-
score) of 4.309-0.0329 + (10*0.00594) + (15*0.00316)-0.598 =
3.7849, which equals 63%. This baseline level of compli-
ance with VAP prevention measures increases by 0.573
(p < 0.001) if a written clinical VAP standard is avail-
able on ICU level, and by 0.244 (p < 0.001) if a VAP sur-
veillance system is in place, which is equivalent to a 15%
and 6% increase in the level of compliance with VAP pre-
vention measures, respectively.
Discussion
Our results indicate that the availability of written guidance
documents (we do not know whether they were really
guidelines or internal guidance documents) to prevent VAP
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Table 2 Results of statistical analyses at the ICU level
(1) (2) (3) (4) (5) (6) (7)
Logistic regression
VAP measure 1
Logistic regression
VAP measure 2
Logistic regression
VAP measure 3
Logistic regression
VAP measure 4
Logistic regression
VAP measure 5
Logistic regression
VAP measure 6
Linear regression
VAP measures 1-6
Availability of VAP guidelines on ICU level 1.803 2.721*** 2.137*** 1.336* 1.456* 2.847*** 0.573***
Existence of VAP surveillance system on
ICU level
1.722 1.320* 1.434** 1.001 1.403* 1.908*** 0.244***
Years of experience in critical care 1.037 1.004 0.992 1.018* 0.996 1.032*** 0.00594*
Female sex 0.874 0.919 1.303 0.677** 0.987 1.095 −0.0329
Number of beds in ICU 0.987 0.996 1.022* 1.013 0.992 1.009 0.00316
ES 1 1 1 1 1 1 0
AR 2.747** 0.189*** 3.179 0.265** 0.617 −0.0933
AT 0.681 1.687* 0.0842*** 1.328 3.800* 1.421 −0.147
AU 2.333 0.0592*** 0.173*** 3.397 −0.222
BE 1.685 0.693 0.0783*** 2.809 2.948 −0.126
BR 3.506** 0.339 1.367 0.119*** 0.267** −0.293
CH 0.720 3.963*** 0.204** 0.531 0.517 3.690 0.146
CO 0.669 1.924 0.343 0.582 0.254** 6.657 −0.00351
DE 0.851 1.982* 0.0889*** 0.885 5.765 1.061 −0.108
FR 0.704 0.426*** 0.0958*** 0.190*** 0.803 4.085*** −0.598***
GB 1.329 6.824*** 0.563 0.0735*** 0.531 1.329 −0.0721
GR 0.694 1.062 0.462 0.168*** 0.101*** 0.955 −0.704**
IN 30.52*** 0.490 0.356* 0.314* 4.880* 0.382***
IT 0.222* 0.908 0.291*** 0.0844*** 0.189*** 0.491** −0.953***
MX 0.650 1.277 0.0506*** 0.584 0.734 1.027 −0.509**
NL 0.108** 2.493 0.0299*** 0.152*** 0.435 1.482 −0.818**
PE 0.506 1.846 0.00364*** 0.839 0.313* 0.198** −1.168***
PT 1.024 0.301** 0.193*** 0.278** 1.164 −0.425**
Constant 4.309***
N 1270 1668 1676 1670 1621 1641 1730
VAP prevention measure 1: Head of bed elevation; VAP prevention measure 2: daily sedation and weaning protocol; VAP prevention measure 3: Oral care with chlorhexidine; VAP prevention measure 4: No ventilator circuit
change unless indicated; VAP prevention measure 5: Cuff pressure control at lease every 24 hrs; VAP prevention measure 6: Strict hand hygiene using alcohol. In column (1) to (6), odds ratios of the logistic regression models
are shown; Column (7) shows non-exponentiated regression coefficients of the linear regression model that was fitted by the least squares approach. In the regression analyses, all 77 countries were included as categorical
variables. For lack of space, however, only those for countries with most responses (n > 20) are shown in the present table. The clustering within pseudo ICUs was taken into account by using robust standard errors (application
of the cluster option in Stata 12). Country appreviations: ES = SPAIN; FR = FRANCE; IT = ITALY; AT = AUSTRIA; GB = UNITED KINGDOM; DE = GERMANY; IN = INDIA; PT = PORTUGAL; AR = ARGENTINA; BE = BELGIUM;
CO = COLOMBIA; MX =MEXICO; NL = NETHERLANDS; CH = SWITZERLAND; AU = AUSTRALIA; GR = GREECE; PE = PERU; BR = BRAZIL.
*p < 0.05, **p < 0.01, ***p < 0.001.
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in ICU patients is significantly associated with compliance
with the prevention measures. A number of interventional
studies exist that analyse adherence with all elements
of previously defined ventilator bundles [19,25,26,34,35].
In a comparative approach, Bouadma et al. [23] analysed
the preventive impact of increased compliance with back-
rest elevation, tracheal cuff pressure maintenance, orogas-
tric tube use, gastric overdistension avoidance, good oral
hygiene and nonessential tracheal suction elimination in a
20-bed medical ICU in a teaching hospital in France [23].
The authors define a composite score of compliance with
the different measures (range, 0–6), and show that after
implementation of the bundle in their ICU, the score sig-
nificantly increased over time, while the VAP prevalence
rate decreased [23]. Although the present analysis also
uses a score of compliance with prevention measures, the
focus however is on the question of why compliance
scores differ across ICUs in the absence of specific inter-
ventions. Interestingly, our results also point out the posi-
tive impact of surveillance systems on compliance with
VAP prevention measures. Although the cause-and-effect
chain between surveillance and prevention measure com-
pliance is still unclear, the efficacy of surveillance systems
in the prevention of hospital acquired infections has been
shown previously [36-39]. Moreover, the results also show
the heterogeneity among European and non-European
countries in the level of compliance with VAP prevention
measures. According to the evidence presented here, this
heterogeneity may to some degree be explained by the
heterogeneity in the availability of standards and the exist-
ence of surveillance system. The ICU-specific cause-and-
effect relationship between availability of standards, and/
or the existence of surveillance system and compliance
with VAP prevention measures, however, is still unclear.
Hence, we cannot exclude that the availability of standards
(and/or surveillance system existence) might be a result
rather than a cause of a high level of awareness of VAP,
which, in turn, results in a high level of compliance with
VAP prevention measures. We may only conclude that on
average, ICUs where standards are available and surveil-
lance systems are in place report a significantly higher
level of compliance with VAP prevention measures irre-
spective of national compliance levels.
It should be noted that there are a number of limita-
tions to the work we present that must be taken into ac-
count. Firstly, to preserve the respondents’ anonymity, the
online questionnaire did not include questions allowing
for identification of the ICU [28]. Accordingly, we were
faced with the problem that the participant’s identity was
unknown. Secondly, the survey did not include rando-
mised sampling, meaning that some categories of ICU
physician might have been overrepresented and that the
country-averages shown in Table 1 cannot be generalized.
Thirdly self-reported compliance might also have been
subject to overreporting. Finally, we do not know what
type of document the respondents were referring to when
confirming the availability of standards on the ICU level.
Overall, there was no possibility to validate any of the
1730 responses.
Conclusions
This study shows wide variability in compliance with VAP-
preventive measures across ICUs in Europe. However, two
things seem to be of special interest for improvement of
compliance: The presence of written standards for man-
agement of mechanically ventilated patients and existence
of an established VAP surveillance system. These two basic
IPC measures should be fostered on a policy level.
Additional file
Additional file 1: Figure S1. VAP Guideline existence and self-reported
preventione measure compliance within and between countries.
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